Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimatoprost - AbbVie

Next Previous
X
Search
Drug Profile

Bimatoprost - AbbVie

Alternative Names: AGN-024; AGN-192024; BUDPF; Glash Vista Cutaneous Solution; GlashVista; Latisse; Lumigan; LumiganRC; LumiganX; Preservative-free bimatoprost ophthalmic solution

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie; Senju Pharmaceutical
  • Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Hypotrichosis; Ocular hypertension
  • Phase II Alopecia

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 28 Feb 2019 Allegran initiates enrolment in a phase-III trial for Glaucoma and Ocular hypertension in USA (Opthalmic) (NCT03850782)
  • 22 Feb 2019 Allergan plans a phase III trial for Glaucoma and Ocular hypertension in USA (Opthalmic) (NCT03850782)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top